Transparency and Pharmaceutical Practice from a MeTA Country

FIP-WHO META Istanbul, Turkey September 5, 2009 1

Normita D. Leyesa, RPh, MS

President, Philippine Pharmacists Association

MeTA Council Member

Transparency and Pharmaceutical Transparency and Pharmaceutical Practice from a MeTA Country:Practice from a MeTA Country:

The MeTA Philippines Country ReportThe MeTA Philippines Country Report

1


Medicine Transparency Alliance Medicine Transparency Alliance (MeTA) initiative proposes to (MeTA) initiative proposes to improve accessimprove access to medicines to medicines through through transparencytransparency and and accountabilityaccountability..


The Philippines Work The Philippines Work Plan for the Phase I Plan for the Phase I 2009-20102009-2010

Objective:Objective:

Provide adequate information that would strengthen decision-making and implementation of processes along the medicines registration, selection, procurement, and use.


Preparation of Preparation of the Work Planthe Work Plan

Identification of priority areas for MeTA Identification of priority areas for MeTA intervention by scoping visits, consultations, and intervention by scoping visits, consultations, and stakeholder mapping stakeholder mapping

Identification of areas supported by other Identification of areas supported by other international development partners and international development partners and stakeholdersstakeholders

Line-up of activities and allocated budget were Line-up of activities and allocated budget were finally deliberated and approvedfinally deliberated and approved


Three Key Points Three Key Points of of Phase IPhase I

1.1. Country structure and commitmentCountry structure and commitment

2.2. Transparency: disclosure, data collection Transparency: disclosure, data collection and analysisand analysis

3.3. Accountability: multi-stakeholder Accountability: multi-stakeholder approach and good governanceapproach and good governance


2009-2010 2009-2010 Strategic Work PlanStrategic Work Plan

Developing Information on Prices, Availability, Developing Information on Prices, Availability, Financing Mechanisms and Rational Drug UseFinancing Mechanisms and Rational Drug Use

Generating Information to Improve Quality of Generating Information to Improve Quality of PharmaceuticalsPharmaceuticals

Setting up Systems for Transparency in Medicines Setting up Systems for Transparency in Medicines Registration, Selection, Procurement and UsageRegistration, Selection, Procurement and Usage

Supporting Transparency Agenda in Decentralized Supporting Transparency Agenda in Decentralized SystemsSystems

Preparation of Budget for the Activities Preparation of Budget for the Activities


KEY OUTCOMESKEY OUTCOMES


Key Outcome 1:Key Outcome 1: Available information on Available information on medicines quality, registration, medicines quality, registration, access, promotions, and rational access, promotions, and rational drug usedrug use

Analysis of existing pharmaceutical data (ongoing)Analysis of existing pharmaceutical data (ongoing) Conduct of Level II and III Survey on medicines Conduct of Level II and III Survey on medicines

(ongoing)(ongoing) Assessment of Public Sector Assessment of Public Sector

– Procurement (including PITC) of medicinesProcurement (including PITC) of medicines– Design of Design of ee-procurement system-procurement system– Assessment of the current systems for financing Assessment of the current systems for financing

medicines for the poor (TOR)medicines for the poor (TOR) Survey of quality of medicines using the “FDA in a Survey of quality of medicines using the “FDA in a

suitcase” suitcase” Study on medicines promotion and advertisement Study on medicines promotion and advertisement

(TOR)(TOR)


Key Outcome 2:Key Outcome 2: Setting up of information Setting up of information structures and systemsstructures and systems

Improvement of the medicines registrationImprovement of the medicines registration

FDA websiteFDA website

Philippine National Drug Formulary Website Philippine National Drug Formulary Website

Support to the implementation of the Electronic Support to the implementation of the Electronic Essential Drug Price Monitoring System (E-EDPMS) at Essential Drug Price Monitoring System (E-EDPMS) at the regional and provincial levelsthe regional and provincial levels

Development of systems for monitoring and Development of systems for monitoring and evaluation of ethical practices of industry and the evaluation of ethical practices of industry and the medical professionmedical profession

Development and testing of monitoring tools for Development and testing of monitoring tools for prescription auditsprescription audits


Key Outcome 3:Key Outcome 3: Improvement of technical Improvement of technical capacity for disclosure, analysis, and capacity for disclosure, analysis, and the use of information and evidencethe use of information and evidence

Pharmaceutical Management and Good Governance Pharmaceutical Management and Good Governance Course for LGU Health Managers and Local Chief Course for LGU Health Managers and Local Chief ExecutivesExecutives

National Good Governance in Medicines AwardsNational Good Governance in Medicines Awards

Strengthening of Drug Therapeutic Committees (DTC) at Strengthening of Drug Therapeutic Committees (DTC) at Regional and Provincial levelsRegional and Provincial levels

Technical capacity building for DTCsTechnical capacity building for DTCs

Development of tools for monitoring/evaluation of DTCsDevelopment of tools for monitoring/evaluation of DTCs

Piloting of the Pharmaceutical Bench BookPiloting of the Pharmaceutical Bench Book


Key Outcome 4:Key Outcome 4:Setting up mechanism for Setting up mechanism for advocacy and participation in advocacy and participation in decision making processesdecision making processes

MeTA Roundtable discussionsMeTA Roundtable discussions PublicationsPublications

– Development of the MeTA WebsiteDevelopment of the MeTA Website – Publication of Proceedings for MeTA ForumPublication of Proceedings for MeTA Forum– Publication of Baseline AssessmentsPublication of Baseline Assessments

Annual MeTA ForumAnnual MeTA Forum


Key Outcome 5:Key Outcome 5: Sustaining a Multi-stakeholder Sustaining a Multi-stakeholder CollaborationCollaboration

MeTA Council and Secretariat OperationsMeTA Council and Secretariat Operations Support to Civil Society OrganizationsSupport to Civil Society Organizations

– Coalition for Health Advocacy and TransparencyCoalition for Health Advocacy and Transparency


““The challenges in transparency and The challenges in transparency and accountability on medicine registration, accountability on medicine registration, selection, procurement, and use in the selection, procurement, and use in the Philippines are enormous. Philippines are enormous.

These can be summed up into two: These can be summed up into two: non-non-accessibility of data accessibility of data to policy, decision to policy, decision makers, and consumers and the makers, and consumers and the lack of lack of tools and structures tools and structures for adequate for adequate reporting, disclosure and feedback.”reporting, disclosure and feedback.”


With the assistance of MeTA With the assistance of MeTA International, and the Department of International, and the Department of International Development (DFID) UK, International Development (DFID) UK, and the support of the World Health and the support of the World Health Organization, we will be able to Organization, we will be able to surmount these challenges and surmount these challenges and ultimately, improve the healthcare ultimately, improve the healthcare delivery system in the Philippines for delivery system in the Philippines for the benefit of the Filipino people.the benefit of the Filipino people.


Thank You!Thank You!

Health & Medicine

Transparency and Pharmaceutical Practice from a MeTA Country